Mineralys Therapeutics (MLYS) Change in Accured Expenses (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Change in Accured Expenses data on file, last reported at -$402000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 74.0% year-over-year to -$402000.0; the trailing twelve-month figure through Mar 2026 stood at $1.6 million (up 127.16% YoY), and the FY2025 full-year result was $427000.0, down 89.74% from the prior year.
• Change in Accured Expenses improved to -$402000.0 in Q1 2026, from -$8.1 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $9.5 million in Q2 2024 to a low of -$16.7 million in Q4 2024.
• A 5-year average of $565588.2 and a median of $864000.0 in 2022 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 2627.14% in 2023, while the deepest fall reached 465.15% in 2023.
• Tracing MLYS's Change in Accured Expenses over 5 years: stood at $846000.0 in 2022, then sank by 461.82% to -$3.1 million in 2023, then slumped by 444.72% to -$16.7 million in 2024, then soared by 51.24% to -$8.1 million in 2025, then soared by 95.06% to -$402000.0 in 2026.
• Business Quant data shows MLYS's Change in Accured Expenses at -$402000.0 in Q1 2026, -$8.1 million in Q4 2025, and $1.0 million in Q3 2025.